CD274 and non-small cell lung carcinoma: To date, the U.S. FDA has approved the use of the ipilimumab and nivolumab combination for the treatment of melanoma, renal cell carcinoma, microsatellite instability-high/mismatch repair-deficient colorectal cancer, hepatocellular carcinoma, PD-L1 positive non-small cell lung cancer, and malignant pleural mesothelioma (134–140).